Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who have poor prognostic ... #3164 Clinical Outcome of B-Cell Chronic lymphocytic Leukemia Following Alemtuzumab Therapy: ... OS time was 19.1 months. About Chronic lymphocytic Leukemia CLL is the most prevalent form of ...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

... FCR and PCR in patients with B-cell chronic lymphocytic leukemia (CLL). The study results will ... active regimens in the treatment of chronic lymphocytic lymphoma (CLL). Promising results have been ... untreated or minimally treated B-cell chronic lymphocytic leukemia. The primary end point of the study was ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... in the treatment of refractory chronic lymphocytic leukemia (CLL). The results demonstrate the ... Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, ... of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006 Sep ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... in patients with relapsed or refractory chronic lymphocytic leukemia, the first large-scale study examining ... the way we treat patients with advanced chronic lymphocytic leukemia," said Linda Burns, M.D., moderator of ... in Relapsed or Refractory Chronic lymphocytic L e ukemia (CLL) Compared with FC Alone: ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... such as prognostic indicators for chronic lymphocytic leukemia (CLL) and side effects such as ... single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Leukine is indicated for use ... p.m. PST) -- Clinical Outcome of B-Cell Chronic lymphocytic Leukemia Following Alemtuzumab Therapy: ...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

... and Antibodies Derived from Chronic lymphocytic Leukemia Cells and Uses Thereof." The patent is ... a drug therapy for patients with B-cell chronic lymphocytic leukemia and other hematologic and ... with refractory or relapsing B-cell Chronic lymphocytic Leukemia ("CLL"). As previously announced, dosing ...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

... trial of SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma will be presented ... CDK 2, 7 AND 9 INHIBITOR, IN CHRONIC lymphocytic LEUKEMIA AND MULTIPLE MYELOMA Abstract #0792 ... evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent ...

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

... of CD19-positive B-cells. About Chronic lymphocytic Leukemia Chronic lymphocytic Leukemia (CLL) is a cancer that affects ... 2007, approximately 15,340 new cases of chronic lymphocytic leukemia will occur in the United States, and ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... disease, follicular lymphoma, mantle cell lymphoma, DLBCL and small lymphocytic lymphoma; all of whom had experienced disease progression despite prior ... (50% ORR), mantle cell lymphoma (32% ORR), DLBCL (30% ORR) and small lymphocytic lymphoma (18% ORR)(1). Patients received everolimus 10 mg daily and ...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

... patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company's proprietary anti-CD37 Small ... / 2 clinical trial (#16007) of TRU-016 for the treatment of CLL and small lymphocytic leukemia (SLL). The objectives of the Phase 1 TRU-016 CLL study were to ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

... suffering from certain subcategories of the disease, especially small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and diffuse large B-cell lymphoma. More details about ...

Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis

... abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current ... The study, titled "B-Cell Clones as Early Markers for Chronic lymphocytic Leukemia," (Vol. 360, No. 7, Feb. 12, 2009) was accompanied by the ...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

... inhibitor of cyclin dependent kinases 2, 7 and 9, in both chronic lymphocytic leukemia and multiple myeloma will be presented. Following are the ... of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic lymphocytic Leukemia and Multiple Myeloma" Poster Board III-260 ...

Genmab Announces Upcoming Ofatumumab Studies

... GEN) announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year. ... CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell ...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

... (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma." It is being ... with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), and to determine the safety ...

Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update

... (SMIP(TM)) drug candidate, for the treatment of chronic lymphocytic leukemia (CLL). The company also announced a new, next-generation product ... activity of TRU- 016 in patients with previously treated CLL or small lymphocytic leukemia. Trubion currently retains all development and commercialization ...

FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data

... Injection for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In a decision issued in response to an appeal filed by ... (International); conference ID number is: 39856497. About Chronic lymphocytic Leukemia CLL is the most common form of leukemia in adults. According to ...

Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission

... (oblimersen sodium) Injection for relapsed or refractory chronic lymphocytic leukemia (CLL). The new data show that patients who achieved complete ... decision to CDER, which is currently pending. About Chronic lymphocytic Leukemia CLL is the most common form of leukemia in adults. According to ...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the ...

Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

... study, and the new trial is intended to address this requirement. Chronic lymphocytic Leukemia (CLL) The Company announced that it will request review of the ... (NDA) for Genasense in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Following FDA's established Dispute Resolution Process, ...

Callisto Reports on Second-Quarter 2007 Milestones

... in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the ...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

... in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

... is now working with leukemia and lymphoma specialists to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML) , acute lymphocytic leukemia (ALL) and other indications. "The IND for thiarabine has been transferred to Access and we have a supply of clinical-grade material." ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... includes two marketed products: TREANDA(R) (bendamustine HCl) for Injection, which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of ...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

... specialists at M.D. Anderson Cancer Center in Houston to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML) , acute lymphocytic leukemia (ALL) and other indications. Additionally, we are actively seeking co-development partners, and believe that thiarabine could have ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment. "The committee's positive ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... tumor types. In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in several cancers, including chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in several cancers, including ...

Creighton Medical Laboratories First to Offer New Cancer Test

... example, with SNP-array virtual karyotypes, we have detected copy neutral LOH at important regions of the cancer genome, like the p53 gene in chronic lymphocytic leukemia. If the tumor has no functional copies of this important gene, it tends to behave aggressively, and the treating physician may want to treat ...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... BioCryst's forodesine Phase 2 single-arm, open-label study evaluating 200 mg of forodesine twice-daily in patients with chronic lymphocytic leukemia is ongoing, and the Company expects to provide an update on this study by the end of 2009. Conference Call and Web Cast ...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

... to undergo apoptosis in various tumor types. In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in hormone-refractory prostate cancer and ...

Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes

... were based on an analysis of the outcomes of 1,240 adults with acute leukemia (707 patients with acute myeloid leukemia and 533 patients with acute lymphocytic leukemia) from 2002 to 2006. Of those patients who received a bone marrow stem cell transplant, 243 were matched at eight out of eight possible HLA ...

The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial

... that it will speed the development and approval of a novel approach aimed at treating patients with fludarabine refractory and/or 17p deleted chronic lymphocytic leukemia (CLL). Doctors at UCSD have already begun treating the first patient with ISF35. They plan to enroll up to twelve patients. These ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

... targets the small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a ...

Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL

... to cancer. Preclinical studies indicate that the catechins present in Polyphenon E may have multiple methods of action. About CLL Chronic lymphocytic Leukemia (CLL) is a type of cancer of the blood and bone marrow that progresses more slowly than acute leukemia. It affects a group of white blood ...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

... B-cell malignancies. MDX-1342 also induces the depletion and elimination of B-cells for inflammatory disease indications. Phase 1 trials in chronic lymphocytic leukemia and rheumatoid arthritis are ongoing with data expected in 2009. -- MDX-1411 is a fully human antibody with enhanced antibody ...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

... preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. XL228 is a small molecule inhibitor ...

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

... B-cell non-Hodgkin's lymphomas (NHL). The abstract reports favorable responses for patients suffering from small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) or from diffuse large B-cell lymphoma (DLBCL), particularly in view of the advanced and refractory stage of the disease in the ...

Trubion Announces Presentation of Positive TRU-016 Data at ASCO

... failed to induce durable responses. TRU-016 is Trubion's proprietary CD37-targeted therapy in development for B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). ASCO Abstract 3074 TRU-016, a small modular immunopharmaceutical (SMIPTM) candidate, targets the ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

... of the initial safety and efficacy findings from this study was recently published (Journal of Clinical Oncology 25:1114, 2007). About Chronic lymphocytic Leukemia CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be ...

Genmab Announces Updates on Phase III Cancer Studies

... included in the planned interim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now received the last scheduled treatment. In order to complete the database and allow for assessment of the responses by an ...